`SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

              [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                         For Quarter Ended June 30, 2001

                                       OR

              [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                        For the transition period from to

                        Commission file number: 000-27847

                      JACOBSON RESONANCE ENTERPRISES, INC.
         ---------------------------------------------------------------
             (Exact Name of Registrant as Specified in its Charter)

    Nevada                                                        65-0684400
 State or other jurisdiction of                                I.R.S. Employer
 incorporation or organization                                Identification No.

             8200 Jog Road, Suite 100, Boynton Beach, Florida 33437
     -----------------------------------------------------------------------
                     (Address of Principal Executive Office)

                                 (561) 752-4141
                              --------------------
               (Registrant's telephone number including area code)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days.      Yes  X   No ___

The number of shares of registrant's Common Stock, $.001 par value, outstanding
as of June 30, 2001 was 55,623,480 shares.




                      JACOBSON RESONANCE ENTERPRISES, INC.

                                      INDEX

                                                                            Page

PART I  - FINANCIAL INFORMATION:

         ITEM 1.  FINANCIAL STATEMENTS

                  Balance Sheet June 30, 2001 and December 31, 2000        4-5

                  Statement of Operations for the Three and Six Months
                  Ended June 30, 2001 and 2000 and for the Period from
                  Inception to June 30, 2001                                6

                  Statement of Changes in Stockholders' Equity from
                  Inception to June 30, 2001                               7-10

                  Statement of Cash Flows for the Six Months Ended
                  June 30, 2001 and 2000 and for the Period from
                  Inception to June 30, 2001                                11

                  Notes to Financial Statements                           12-13

         ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS                    14-17

PART II  - OTHER INFORMATION:

         ITEM 1.  LEGAL PROCEEDINGS                                         17

         ITEM 2.  CHANGES IN SECURITIES                                     17

         ITEM 3.  DEFAULTS UPON SENIOR SECURITIES                           17

         ITEM 4.  SUBMISSIONS OF MATTERS TO A VOTE OF
                      SECURITY HOLDERS                                      17

         ITEM 5.  OTHER EVENTS                                              17

         ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K                          17

SIGNATURES                                                                  18

                                       2


                           FORWARD LOOKING STATEMENTS

     When used in this report, the words "may, will, expect, anticipate,
continue, estimate, project or intend" and similar expressions identify
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E Securities Exchange Act of 1934 regarding events,
conditions and financial trends that may effect our future plan of operation,
business strategy, operating results and financial position. Current
stockholders and prospective investors are cautioned that any forward-looking
statements are not guarantees of future performance and are subject to risks and
uncertainties and that actual results may differ materially from those included
within the forward-looking statements as a result of various factors. Such
factors are described under the headings "Business-Certain Considerations,"
"Management's Discussion and Analysis of Financial Condition and Results of
Operations," and the financial statements and their associated notes.

     Important factors that may cause actual results to differ from projections
include, for example:
     o    the success or failure of management's efforts to implement their
          business strategy;
     o    our ability to protect our intellectual property rights;
     o    our ability to compete with major established companies;
     o    our ability to attract and retain qualified employees; and
     o    other risks which may be described in future filings with the SEC.

                                       3


                         JACOBSON RESONANCE ENTERPRISES, INC.
                            (A DEVELOPMENT STAGE ENTERPRISE)
                                      BALANCE SHEET

                                                June 30,            December 31,
                                                 2001                  2000
                                              (Unaudited)
                                             ------------          -------------
CURRENT ASSETS

    Cash and Cash Equivalents                $   26,622             $  218,770

    Accounts Receivable                           3,972                 21,688

    Due from Officer/Shareholder                 50,000                 50,000

    Prepaid Expenses and Other                   23,956                 42,237
                                             ------------          -------------

        Total Current Assets                    104,550                332,695


    Property and Equipment, at Cost,
       (Net of Accumulated

        Depreciation of $71,499 and
          $56,438, respectively)                140,569                188,830

    Deposits                                      1,395                  1,395

    Due from Officer/Shareholder, Net
      of Allowance for Doubtful Amounts
      of $200,000                                    -                      -

    Deferred Income Tax Asset, Net of
      Valuation Allowance of $2,164,596 and
      $1,968,000, respectively)                      -                      -
                                             ------------          -------------
        Total Assets                          $ 246,514             $  522,920
                                             ============          =============

  The accompanying notes are an intergral part of these financial statements.

                                       4


                        LIABILITIES AND STOCKHOLDERS' DEFICIENCY


CURRENT LIABILITIES

    Accounts Payable and Accrued Expenses     $ 170,773             $  175,350

    Litigation Settlement Payable             1,000,000              1,000,000

    Deposits on Common Stock to be Issued           720                 69,397

    Other Liabilities                            20,000                     -

    Notes Payable                               175,000                     -
                                             ------------          -------------
        Total Current Liabilities             1,366,493              1,244,747
                                             ------------          -------------

STOCKHOLDERS' DEFICIENCY

    Preferred Stock $.001 Par Value,
        5,000,000 Shares Authorized;
        Issued and Outstanding,
           30,000 Shares                             30                     30

    Common Stock, $.001 Par Value,
        300,000,000 Shares Authorized;
        Issued and Outstanding, 55,623,480
          and 54,815,336 Shares,
          respectively                           55,623                 54,815

    Additional Paid in Capital                8,665,228              8,427,840

    Deficit Accumulated During
       the Development Stage                 (9,796,186)            (9,159,838)

    Common Stock in Treasury
       (600,000 Shares at Cost)                    (600)                  (600)

    Subscriptions Receivable                    (44,074)               (44,074)
                                             ------------          -------------
        Total Stockholders' Deficiency       (1,119,979)              (721,827)
                                             ------------          -------------
        Total Liabilities and
           Stockholders' Deficiency         $   246,514            $   522,920
                                            =============          =============

  The accompanying notes are an intergral part of these financial statements.

                                       5


                      JACOBSON RESONANCE ENTERPRISES, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
                             STATEMENT OF OPERATIONS

                                   (Unaudited)


                                                                                            For the Period
                                     For the Three Months         For the Six Months        from Inception
                                        Ended June 30,              Ended June 30,            to June 30,
                                     2001            2000        2001            2000            2001
                                   ------------------------    ------------------------    ----------------

REVENUES                           $  17,648     $   4,675     $  24,734     $   7,250       $   203,447
                                   ----------    ----------    ----------    ----------      ------------
COSTS AND EXPENSES:
    General and Administrative       303,031       335,689       692,530       947,894         5,347,122
    Research and Development          15,121        26,630        47,823       125,665         1,000,204
    Settlement Costs                      -             -             -             -          1,870,000
    Financing Costs                       -             -             -             -          2,095,704
                                   ----------    ----------    ----------    ----------      ------------
      Total Operating Expenses       318,152       362,319       740,353     1,073,559        10,313,030
                                   ----------    ----------    ----------    ----------      ------------
Other Income (Expense)
    Interest Income                    2,361        21,951         9,260        29,295           104,641
    Interest Expense                 (16,819)           -        (16,819)           -            (16,819)
    Gain on Sales of
       Resonance Machines             19,628            -         86,830            -            225,545
                                   ----------    ----------    ----------    ----------      ------------
NET LOSS                          $ (295,334)    $(335,693)    $(636,348)  $(1,037,014)      $(9,796,186)
                                  ===========    ==========    ==========  ============      ============


PER SHARE INFORMATION:

Net Loss Per Share:
    Basic                          $   (0.01)    $   (0.01)    $   (0.01)   $    (0.02)
                                  ===========   ===========   ===========  ============
    Diluted                        $   (0.01)    $   (0.01)    $   (0.01)   $    (0.02)
                                  ===========   ===========   ===========  ============

Shares Used to Compute
  Net Loss Per Share
    Basic                         55,623,480    46,731,058    55,426,220    42,352,977
                                  ===========   ===========   ===========  ============
    Diluted                       55,623,480    46,731,058    55,426,220    42,352,977
                                  ===========   ===========   ===========  ============

  The accompanying notes are an intergral part of these financial statements.

                                       6



                      JACOBSON RESONANCE ENTERPRISES, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
                  STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
                 For the Period form Inception to June 30, 2001
                                   (Unaudited)

                                                               COMMON STOCK                    PREFERRED STOCK
                                                     -------------------------------      ------------------------
                                                         ISSUED             AMOUNT          ISSUED          AMOUNT
                                                     -------------------------------      ------------------------

 Issuance of Founders Stock at Par $.001              57,220,000          $ 57,220            -              $  -

 Recapitalization - June 4, 1996                       4,905,000             4,905            -                 -

 Issuance of Common Stock at $.10 Per Share           10,000,000            10,000            -                 -

 Issuance of Common Stock at $1.75 Per Share              18,857                19            -                 -

 Purchase of Treasury Stock at Cost                           -                 -             -                 -

 Conversion of Common Stock to Preferred Stock       (45,000,000)          (45,000)       45,000                45

 Net Loss                                                     -                 -             -                 -
                                                     ------------      ------------     ---------        ----------
 Balance, December 31, 1996                           27,143,857            27,144        45,000                45

 Issuance of Common Stock for Services Rendered at
     Prices Between $.15 and $1.75 Per Share              40,114                40            -                 -

 Issuances of Common Stock from Private Placement at
     Prices Between $.15 and $.25 Per Share              760,000               760            -                 -

 Issuances of Common Stock out of Proceeds of
     Subscription Receivable                                  -                 -             -                 -

 Net Loss                                                     -                 -             -                 -
                                                     ------------      ------------     ---------        ----------
 Balance, December 31, 1997                           27,943,971            27,944        45,000                45

Reacquisition of Common Shares and                    (3,000,000)           (3,000)           -                 -
  Collection of Subscription Receivable

Cash Collection of Subscription Receivable                    -                 -             -                 -

Issuance of Common Stock from Private
   Placement at a Price of $.15 per Share              4,675,850             4,676            -                 -

Issuance of Common Stock from Private
   Placement at a Price of $.35 per Share              2,017,999             2,018            -                 -

Issuance of Common Stock for Services
   Rendered at Prices between $.15 and $.35 per Share    663,223               663            -                 -

Fair Value of Options Issued to Consultants                   -                 -             -                 -

Net Loss                                                      -                 -             -                 -
                                                     ------------      ------------     ---------        ----------
Balance December 31, 1998                             32,301,043            32,301        45,000                45


  The accompanying notes are an intergral part of these financial statements.

                                       7


-Continued-


                   DEFICIT
                 ACCUMULATED
 ADDITIONAL        DURING                             COMMON       STOCKHOLDERS'
  PAID-IN        DEVELOPMENT      SUBSCRIPTION       STOCK IN         EQUITY
  CAPITAL           STAGE          RECEIVABLE        TREASURY      (DEFICIENCY)
-------------   -------------    -------------     -----------     ------------

 $ (57,220)         $   -           $   -             $    -          $   -

    (4,905)             -               -                  -              -

   990,000              -         (526,550)                -         473,450

    32,981              -               -                  -          33,000

        -               -               -                (600)          (600)

    44,955              -               -                  -              -

        -         (292,325)             -                  -        (292,325)
-------------   -------------    -------------     -----------     ------------

 1,005,811        (292,325)       (526,550)              (600)       213,525

    12,744              -               -                  -          12,784

   139,240              -               -                  -         140,000

        -               -            5,000                 -           5,000

        -         (315,319)             -                  -        (315,319)
-------------   -------------    -------------     -----------     ------------
 1,157,795        (607,644)       (521,550)              (600)        55,990

  (450,000)             -          450,000                 -          (3,000)

        -               -           27,476                 -          27,476

   659,294              -               -                  -         663,970

   690,156              -               -                  -         692,174

   176,415              -               -                  -         177,078

     2,063              -               -                  -           2,063

        -         (952,276)             -                  -        (952,276)
-----------    ------------    ------------       ------------   ------------
 2,235,723      (1,559,920)        (44,074)              (600)       663,475




  The accompanying notes are an intergral part of these financial statements.

                                       8



                      JACOBSON RESONANCE ENTERPRISES, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
            STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Continued)
                 For the Period from Inception to June 30, 2001
                                   (Unaudited)



                                                      COMMON STOCK                     PREFERRED STOCK
                                                ---------------------------       ----------------------------
                                                ISSUED               AMOUNT       ISSUED               AMOUNT
                                              -----------           ----------   ---------           ----------

Balance December 31, 1998                   32,301,043               32,301       45,000                 45

Issuance of Common Stock for Services
   Rendered at Prices between $.18 and
    $2.69 per Share                          1,313,903                1,314           -                  -

Issuance of Common Stock  for Repayment
  of Debt                                      291,305                  291           -                  -

Issuance of Common Stock for Exercise
  of Warrants                                  900,000                  900           -                  -

Sales of Shares at $.20 per Share              500,000                  500           -                  -

Beneficial Conversion Feature on
   Convertible Debentures                           -                    -            -                  -

Issuance of Common Stock for
   Conversion of Debentures                  1,862,876                1,863


Net Loss                                            -                    -            -                  -
                                             -----------          ------------   -----------        ------------
 Balance, December 31, 1999                 37,169,127               37,169       45,000                 45

Issuance of Common Stock for Services
  Rendered at Prices between $.21 and
   $1.52 per Share                             385,342                  385           -                  -

Sales of Shares a $.13 to $.65 per Share     2,120,867                2,121           -                  -

Fair Value of Options Issued to Consultants         -                    -            -                  -

Fair Value of Options Issued on Settlement          -                    -            -                  -

Issuance of Common Stock for Exercise
  of Options                                   140,000                  140           -                  -

Issuance of Common Stock Upon Conversion
  of Preferred Stock                        15,000,000               15,000      (15,000)               (15)

Net Loss                                            -                    -            -                  -
                                           -----------            ------------   -----------        ------------
Balance, December 31, 2000                  54,815,336               54,815       30,000                 30

Issuance of Common Stock for Services
  Rendered at Prices between $.30 and
  $.35 per Share                               210,112                  210           -                  -

 Issuances of Common Stock from Private
   Placements at Prices Between $.25 and
   $.42 Per Share                              598,032                  598           -                  -

Net Loss                                            -                    -            -                  -
                                           -----------          ------------   -----------        ------------

Balance, June 30, 2001                     55,623,480           $    55,623       30,000             $   30
                                           ============         ============   ===========        ============

  The accompanying notes are an intergral part of these financial statements.

                                       9


-Continued-


                   DEFICIT
                 ACCUMULATED
  ADDITIONAL        DURING                            COMMON        STOCKHOLDERS'
   PAID-IN       DEVELOPMENT     SUBSCRIPTION        STOCK IN         EQUITY
   CAPITAL         STAGE           RECEIVABLE        TREASURY      (DEFICIENCY)
-------------   -------------   ---------------   --------------   --------------

2,235,723      (1,559,920)          (44,074)           (600)          663,475

  420,375              -                 -               -            421,689

   60,883              -                 -               -             61,174

1,754,100              -                 -               -          1,755,000

   99,500              -                 -               -            100,000

  333,332              -                 -               -            333,332

  902,194              -                 -               -            904,057

       -       (3,657,966)               -               -         (3,657,966)
-------------   -------------   ---------------   --------------   -------------
5,806,107      (5,217,886)          (44,074)           (600)          580,761

  378,555              -                 -               -            378,940

1,095,497              -                 -               -          1,097,618

  242,031              -                 -               -            242,031

  870,000              -                 -               -            870,000

   50,635              -                 -               -             50,775

  (14,985)             -                 -               -                 -

       -       (3,941,952)               -               -         (3,941,952)
-------------   -------------   ---------------   --------------   -------------
8,427,840      (9,159,838)          (44,074)           (600)         (721,827)

   70,938              -                 -               -             71,148

  166,450              -                 -               -            167,048

       -         (636,348)               -               -           (636,348)
-------------   -------------   ---------------   --------------   -------------

$8,665,228    $(9,796,186)       $  (44,074)        $   (600)      $(1,119,979)
=============   =============   ===============   ==============   =============

  The accompanying notes are an intergral part of these financial statements.

                                       10



                      JACOBSON RESONANCE ENTERPRISES, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
                             STATEMENT OF CASH FLOWS
                                   (Unaudited)

                                                                                                                 For the Period
                                                                                                                 from Inception
                                                                  For the Six Months Ended June 30,               to June 30,
                                                                   2001                      2000                    2001
                                                            -------------------       -------------------      ------------------
CASH FLOWS FROM OPERATING ACTIVITIES:
    Net Loss                                                    $ (636,348)              $(1,037,014)            $ (9,796,186)
    Adjustments to Reconcile Net Loss to Net Cash
       Used in Operating Activities:
            Depreciation                                            20,341                    18,522                   76,779
            Amortization                                                 -                         -                    7,742
            Allowance for Doubtful Amounts Due
              from Officer/Shareholder                                   -                         -                  200,000
            Write off of Licensing Costs                                 -                         -                  126,582
            Fair Value of Common Stock Issued
              for Services Rendered                                 71,148                   368,000                1,061,857
            Fair Value of Common Stock Issued
              for Interest Expense                                       -                         -                    6,781
            Stock Issued for Conversion of
              Warrants Attributed to Interest                            -                         -                1,754,100
            Beneficial Conversion Feature of
              Debentures                                                 -                         -                  333,332
            Fair Value of Options Issued                                 -                    55,301                1,114,094
            Disposition of Fixed Assets                             31,238                         -                   31,238

        Changes is Operating Assets and Liabilities:
            Accounts Receivable                                     17,716                         -                   (3,972)
            Prepaid Expenses and Other                              18,281                    10,561                  (23,956)
            Deposits                                                     -                    (3,245)                  (1,395)
            Accounts Payable and Accrued Expenses                   (4,577)                  (16,950)                 170,773
            Other Liabilities                                       20,000                         -                   20,000
            Litigation Settlement Payable                                -                         -                1,000,000
                                                            -------------------       -------------------      ------------------

Net Cash Used in Operating Activities                             (462,201)                 (604,825)              (3,922,231)
                                                            -------------------       -------------------      ------------------

CASH FLOWS FROM INVESTING ACTIVITIES:
    Purchase of Property and Equipment                              (3,318)                  (62,094)                (248,586)
    Loans made to Shareholder and Employee                               -                  (250,000)                (250,000)
    Payment for Licensing Costs                                          -                         -                 (126,582)
                                                            -------------------       -------------------      ------------------

Cash Used in Investing Activities                                    (3,318)                 (312,094)               (625,168)
                                                            -------------------       -------------------      ------------------

CASH FLOWS FROM FINANCING ACTIVITIES:
    Purchase of Treasury Stock                                            -                         -                    (600)
    Proceeds from Notes Payable                                     175,000                         -                 235,000
    Proceeds from Issuance of Debentures                                  -                         -                 890,490
    Proceeds from Exercise of Warrants                                    -                         -                     900
    Proceeds from Exercise of Options                                     -                    34,775                  50,775
    Proceeds from Common Stock to be Issued                             720                         -                  70,117
    Proceeds from Issuance of Common Stock
        from Subscriptions Receivable                                     -                         -                 653,976
    Proceeds from Issuance of Common Stock                           97,651                 1,113,620               2,673,363
                                                            -------------------       -------------------      ------------------

Net Cash Provided by Financing Activities                           273,371                 1,148,395               4,574,021
                                                            -------------------       -------------------      ------------------
Net Increase (Decrease) in Cash and Cash Equivalents               (192,148)                  231,476                  26,622

Cash and Cash Equivalents - Beginning of Period                     218,770                   579,518                      -
                                                            -------------------       -------------------      ------------------
Cash and Cash Equivalents - End of Period                          $ 26,622                 $ 810,994                $ 26,622
                                                            ===================       ===================      ==================
NONCASH INVESTING AND FINANCING ACTIVITIES:

  Issuance of Common Stock for Repayment of Debt                   $      -                 $       -                $ 60,000
                                                            ===================       ===================      ==================
  Issuance of Common Stock for Deposits                            $ 69,397                 $       -                $ 69,397
                                                            ===================       ===================      ==================
  Subscriptions Receivable for Issuance of Common Stock            $      -                 $       -               $ 698,050
                                                            ===================       ===================      ==================
  Conversion of debentures into common stock                       $      -                 $       -              $1,000,000
                                                            ===================       ===================      ==================


  The accompanying notes are an intergral part of these financial statements.

                                       11


                      JACOBSON RESONANCE ENTERPRISES, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
                          NOTES TO FINANCIAL STATEMENTS
                     For the Six Months Ended June 30, 2001
                                   (Unaudited)



NOTE 1 - BASIS OF PRESENTATION

The accompanying financial statements for the interim period are unaudited and
reflect all adjustments (consisting only of normal recurring adjustments) which
are, in the opinion of management necessary for a fair presentation of the
financial position and operating results for the periods presented. These
financial statements should be read in conjunction with the financial statements
and notes thereto, together with Management's Discussion and Analysis of
Financial Condition and Results of Operations, contained in the Annual Report on
Form 10-KSB for the year ended December 31, 2000, of Jacobson Resonance
Enterprises, Inc. (the "Company") as filed with the Securities and Exchange
Commission. The results of operations for the three and six months ended June
30, 2001 are not necessarily indicative of the results for the full fiscal year
ending December 31, 2001.

NOTE 2 - NOTES PAYABLE

In the second quarter of 2001, the Company received $175,000 from the proceeds
of several promissory notes. Each of these notes is for a term of 60 days and
bears interest at a rate of 5% per annum. At June 30, 2001, the Company was in
default on $75,000 of these notes.

Under the terms of the notes, in the event of default, the note holder has the
option to purchase 10,000 shares of the Company's common stock for $100 for each
$25,000 of outstanding debt. At June 30, 2001, the Company had received $300 for
30,000 shares. The $300 is included in the accompanying balance sheet as
deposits on common stock to be issued as the shares have not yet been issued.

Additionally, the notes state that the note holders can continue to purchase
common stock in the Company at a rate of 5,000 shares of common stock for $50
for each $25,000 of outstanding debt for each 30 day period until the notes are
paid in full. The Company is recording interest expense for the difference
between the fair market value of the Company's common stock on the date the loan
proceeds are received and the exercise price of $.01 per common share for any
shares that the note holders have a right to receive. The interest charge for
the quarter ended June 30, 2001 was approximately $15,000.


NOTE 3 - STOCKHOLDERS' EQUITY

In January 2001, the Company issued 210,112 shares of common stock at prices
between $.30 and $.35 for services which included 165,000 shares under a
continuing agreement for endorsement. An aggregate of $71,148 was charged to
operations during the six months ended June 30, 2001.

                                       12


                      JACOBSON RESONANCE ENTERPRISES, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
                          NOTES TO FINANCIAL STATEMENTS
                     For the Six Months Ended June 30, 2001
                                   (Unaudited)


NOTE 3 - STOCKHOLDERS' EQUITY(continued)

In March 2001, the Company issued common stock pursuant to two private
placements. In the first private placement, the Company issued 198,032 shares of
common stock at a price of $.42 per share (Including 165,232 shares for $69,397
received in 2000). The Company still owes 1,000 shares related to this private
placement. Under the terms of this private placement, investors received one
Class A warrant which are exercisable at $.63 per common share for a four-year
period extending through December 31, 2004 and potentially one Class B warrant
which will be issued when and if the Class A warrants are exercised on or before
December 31, 2001 which are exercisable at $.84 per common share for a five-year
period extending through December 31, 2005 for each share of common stock
purchased.

In March, the Company issued 400,000 shares of common stock at $.25 per share
under the terms of the second private placement which has been closed.

                                       13


ITEM 2.MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
       OPERATIONS

     Certain statements contained in this report, including, without limitation,
statements containing the words "believes," "anticipates," "expects" and words
of similar import constitute "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks and uncertainties. The Company's
actual results may differ materially from those anticipated in these
forward-looking statements as a result of certain factors, including the success
and subsequent acceptance of new medical research and development; the
regulatory framework of the health care industry; the Company's ability to
create, sustain, manage or forecast its growth; its ability to attract and
retain key personnel; its ability to protect technology; changes in its business
strategy or development plans; competition; demographic changes; business
disruptions; adverse publicity; and international, national and local general
economic and market conditions.

PLAN OF OPERATION

     The Company is in the development stage and has received some revenues from
RealPure licensing operations during the second  quarter of 2001. It incurred
losses of $636,348 for the six months ended June 30, 2001. It has incurred
losses of $9,796,186 since its inception. Of that amount, $4,270,164 represents
the non-cash expense resulting from the issuance of common stock and options to
purchase common stock to members of the Company's  management and third parties
for services rendered and interest.

2001 Operations Compared to 2000

     The net loss decreased from $1,037,014 to $636,348 for the six months ended
June 30, 2000 as compared to June 30, 2001. In addition, the net loss decreased
from $335,693 to $295,334 for the three months ended June 30, 2001 as compared
to June 30, 2000.  This change is primarily as a result of a decrease in noncash
compensation for the six months ended June 30, 2001 of approximately $297,000.

     In early May 2000, the Company launched its marketing campaign for
resonated drinking products at The Brett Favre Forward Foundation Charity
Celebrity Golf Tournament in Biloxi, Mississippi. Brett Favre is the official
spokesperson for the resonated Spring Water and Real-Pro Hi-Energy Sports Drink
produced by RealPure Beverage Group, LLC, a licensee of the Company. The Company
has received limited royalties from RealPure in connection with product sales.
At the end of August 2000, at the Company's annual shareholders meeting in Las
Vegas, Nevada, the President of RealPure Beverage Group, Mr. David Cox, provided
the Company with marketing and distribution plans covering 2001 product
development and distribution efforts. Of particular interest would be the
introduction during 2001 of a pediatric supplement beverage to aid newborns and
infants in the assimilation and digestion of food as well as to provide energy
and reduce gas.
                                       14


     In addition, the Company has received approval and a CE Mark from the
European Union, thus allowing distribution and commercialization of its
resonators for chronic pain of the knee (including arthritis) indications. The
Company also received approval by Health Canada in November 2000, allowing the
Company to begin commercialization initiatives in Canada. The first medical
centers in Canada became operational prior to the end of first quarter of 2001.
Additional health clearances and approvals have been granted and received by the
Company for use and distribution of resonators in Australia, Mexico, Finland and
Norway. The Company expects FDA approval of its 18-inch clinical Jacobson
Resonator sometime in mid 2001 for treatment of chronic pain from osteoarthritis
of the knee, and further approval for treatment of the entire spectrum of
chronic pain sometime in late 2001 or early 2002. Receipt of this approval will
allow the Company's distribution network to make, market, distribute and sell
those clinical products on a commercial basis in the United States of America.
The Company's agricultural and aquacultural initiatives continue to show
tremendous potential and interest in the Pan Asian market. As a result, the
Company is working on licensing and joint venture opportunities in the region,
from which is expects to generate additional revenue. Research at Texas A&M
University, Mississippi State University and the University of Oklahoma have
shown positive results that Jacobson Resonance Technology can beneficially
affect the growth cycle of vegetables and fruits. The foregoing combination of
events is expected to generate ongoing revenue for the Company and therefore
bring it out of the development stage into the operating stage during the middle
of 2001.

     Other possible sources of revenue for the Company during fiscal 2001
include the following:

     1.   Licensing revenue from a larger medical products company for the
          development, marketing and distribution rights in connection with the
          use of Jacobson Resonance in the treatment of cardiac arrhythmia. The
          Company thinks that interest in such licensing arrangement will be
          generated by the publication of the results of the completed research
          in cardiac pacing at the University of Oklahoma Health Sciences Center
          that Jacobson Resonance is effective in the treatment of cardiac
          arrhythmia on dogs.

     2.   Licensing revenue from O2 Marketing Group,  Inc., a manufacturer of
          consumer-oriented oxygen products for the cosmetics, nutraceutical and
          pharmaceutical industries, for an exclusive license to use Jacobson
          Resonance for not less than ten years  covering the Republic of South
          Africa.  The Company  has a letter of intent with O2 and is currently
          negotiating a definitive license arrangement.

     3.   Licensing revenue from Palmer Natural Products, Inc. and Perfect
          Living Systems, Inc., two nutraceutical laboratories and formulary
          companies located in southern California. These companies plan to use
          Jacobson Resonance technology and equipment on the formulary of
          multiple nutraceuticals, as well as client-specific products, for
          manufacture, marketing, distribution and sale. The Company signed a
          letter of intent with these companies in April 2000 and is evaluating
          entering into a licensing agreement.

     4.   Licensing revenue from existing licensee for building/construction and
          the environment from Enviro Brick and Block Ltd. The Company has had a
          signed licensing exclusive agreement since August 2000. Revenues from
          Enviro Block are expected by the second quarter of 2002.

                                       15


     5.   Licensing revenue from Comercializadora de Calidad S.A. of Guatemala,
          for the distribution of resonators and the establishment of treatment
          centers throughout Panama, El Salvador, Costa Rica and Guatemala. The
          Company signed a letter of intent with the Guatemalan distributor in
          March 2000.

     6.   Increases in revenue from its existing licensees for the clinical
          Jacobson Resonators because of additional FDA approvals and CE
          Marking. The Company also plans to seek CE Marking of the other two
          clinical models of the Jacobson Resonator.  These approvals would
          broaden the product line in both the United States of America and
          Europe, and would broaden applications for the clinical Jacobson
          Resonators in the United States of America.

     7.   Increased revenues through Serrato Europe and EKINSA distribution and
          marketing of resonators in South America, Europe and the Middle East.

     The Company will continue both use and product research and development for
Jacobson Resonance. The Company estimates that the currently ongoing university
research will require about $460,000 of the Company's funds for the year 2001.
It anticipates continued prototyping of additional models of the Jacobson
Resonator for varying uses if additional funds become available for that
purpose. It estimates that the costs to the Company of such prototyping will be
approximately $150,000.

LIQUIDITY AND CAPITAL RESOURCES AS OF JUNE 30, 2001

     The Company's cash on hand at June 30, 2001, was $26,622, as compared to
$71,469 at March 31, 2001. Revenues for the quarter ended June 30, 2001 were
$17,648, as compared to $4,675 for the quarter ended June 30, 2000. The Company
had a net loss of $636,348 for the six months ended June 30, 2001 as compared to
a net loss of $1,037,014 for the six months ended June 30, 2000. This change is
primarily as a result of a decrease in noncash compensation for the six months
ended June 30, 2001 of approximately $297,000.

     Since the beginning of the year, the Company has received approximately
$98,000 from the sale of securities and $175,000 from the proceeds of several
notes payable, the details of which can be found in Note 2. The Company
anticipates that its existing resources will be sufficient to fund its plan of
operation through 2001. By the latter part of 2001, the Company expects to be
generating sufficient revenue to fund its plan of operation. However, if the
Company by that time is not generating any revenue or is generating insufficient
revenue for such funding, then the Company may have to seek additional funds
through either debt or equity financing. The Company's year-end financial
statements include an explanatory paragraph about the Company's ability to
continue as a going concern.

                                       16


     The Company entered into a retainer agreement with the law firm of Jackson
Campbell, P.A., Washington, D.C. as financial consultants and corporate
representatives on special projects.

     The Company also entered into an agreement in April 2001 with Regulatory
Insight, Inc., Lakewood, Colorado for healthcare consulting services and to
oversee the Company's new healthcare initiatives, filings and FDC compliance.

     The Company also entered into an agreement in June 2001 with 1st Source
Communications, Los Angeles, California for services relating to enhancing
investor relations program and opportunities.

                           PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

     The Company is not involved in any legal proceedings or litigation, and the
officers and directors are aware of no other pending litigation. The Company and
Dr. Jerry Jacobson are, however, seeking sources of equity financing for the
purpose of satisfying the terms and conditions of a settlement agreement with
Eric Hewko and Patrick Casey entered into on March 2, 2001. Dr. Jacobson filed
for bankruptcy and on December 6, 2000, the case was dismissed.

ITEM 2.  CHANGES IN SECURITIES

         None.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

         None

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         None.

ITEM 5.  OTHER EVENTS

         None.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8_K

         There were no reports on Form 8-K filed by the registrant for the
         quarter ending June 30, 2001

                                       17


                                   SIGNATURES

     Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.


                      JACOBSON RESONANCE ENTERPRISES, INC.

Date: August 7, 2001                    By:    /s/ Jerry I. Jacobson
                                        ------------------------------------
                                        Jerry I. Jacobson, Chairman of the Board
                                              and Chief Executive Officer

     Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the date indicated.

Date: August 7, 2001                    By:   /s/ Jerry I. Jacobson
                                        ------------------------------------
                                        Jerry I. Jacobson, Chairman of the Board
                                              and Chief Executive Officer
                                              (Principal Executive Officer)

Date: August 7, 2001                    By:   /s/ Debra M. Jacobson
                                        ------------------------------------
                                        Debra M. Jacobson, Director, Senior Vice
                                            President, Treasurer and Secretary
                                              (Principal Financial and
                                                  Accounting Officer)


                                       18`